As with all medications in the GLP-1 class, Foundayo includes safety labeling regarding thyroid risks observed in animal studies
[21] Weight loss associated with these medications may also influence cardiovascular parameters, though the relationship is complex
doi:10.1210/endocr/bqaf028 Lhteenvuo M, Tiihonen J, Solismaa A, Tanskanen A, Mittendorfer-Rutz E, Taipale H
However, this paradigm is shifting as health systems recognize the substantial cardiovascular benefits demonstrated in dedicated outcomes trials
In some instances these effects can be directly linked to the shuttling activity, whereas in other cases, the mechanism by which these effects are achieved remain unclear
The long-term benefits of glucose control on the eyes far outweigh any acute risk